Last reviewed · How we verify

NCT03450239

Functional Magnetic Resonance Imaging (fMRI) Investigation Into Compulsivity in Anorexia

Completed NA Last updated 5 April 2018
What this trial tests

NA trial testing MRI in Anorexia Nervosa in Remission (Disorder) in 40 participants. Completed in 7 February 2018.

Timeline
5 May 2017
Primary endpoint
7 February 2018
7 February 2018

Quick facts

Lead sponsorUniversity of Oxford
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment40
Start date5 May 2017
Primary completion7 February 2018
Estimated completion7 February 2018
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Oxford

Who can join

Adults 18 to 40, female only, with Anorexia Nervosa in Remission (Disorder) or Compulsive Behavior. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will examine compulsivity in those who have recovered from anorexia nervosa, using a multi-modal MRI study. The neural activation of key fronto-striatal areas will be explored using a task which examines set-shifting and reversal-learning, two key components of compulsivity. Additionally, the functional networks displayed during resting-state MRI will be examined between groups, as will the neurochemicals present (using Magnetic Resonance spectroscopy).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

Other University of Oxford trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03450239.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing